

WE'RE HERE FOR YOUR RYBELSUS® PATIENTS

THE RYBELSUS® REIMBURSEMENT NAVIGATION PROGRAM

If your patient has questions about insurance coverage and eligibility, our reimbursement navigation specialist can help provide answers and navigate their coverage.



QUESTIONS? CALL:
1-888-598-0420

The Rybelsus® Reimbursement Navigation Program offers your patients help with insurance reimbursement navigation. Enrol your Rybelsus® patient into the Rybelsus® Reimbursement Navigation Program today!



All trademarks owned by Novo Nordisk A/S and used by Novo Nordisk Canada Inc.
Novo Nordisk Canada Inc., Tel: (905) 629-4222
or 1-800-465-4334. www.novonordisk.ca
© 11/2020 Novo Nordisk Canada Inc. CA20RYB00023E



RYBELSUS®
semaglutide tablets



The Rybelsus[®] Reimbursement Navigation Program is a patient assistance service designed to help patients understand and navigate the drug reimbursement options that may be available. This program is managed by Novo Nordisk Canada Inc. ("Novo Nordisk") and is administered by a third party service provider in Canada for Canadian residents only. This program is only available for patients that have been prescribed Rybelsus[®] by their healthcare professional. This program and the services provided can be terminated at the discretion of Novo Nordisk.

PATIENT INFORMATION	Name of patient: _____		Age: _____	Sex: Male <input type="checkbox"/> Female <input type="checkbox"/>
	Address (include Apt #): _____		City: _____	Province: _____
	Home number: _____	Preferred method of communication: _____	Phone <input type="checkbox"/> Email <input type="checkbox"/> _____	
	Alternate number: _____	Preferred time: _____	Morning <input type="checkbox"/>	Afternoon <input type="checkbox"/>
	Permission to leave voicemail: Yes <input type="checkbox"/> No <input type="checkbox"/>		Permission to send email: Yes <input type="checkbox"/> No <input type="checkbox"/>	
PATIENT AUTHORIZATION	_____		_____	
	Patient (signature)		Patient (print)	
RYBELSUS[®]	Rybelsus [®] (semaglutide tablets)		Date of prescription: _____	
			(mm/dd/yyyy)	
MEDICAL HISTORY	Current antihyperglycemic treatment and dose: _____		Patient weight: _____	
	Past antihyperglycemic treatment and dose: _____		Patient height: _____	

(continued on reverse)

RYBELSUS[®] (semaglutide tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus:

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in combination with other medicinal products for the treatment of diabetes (see clinical trials in the Product Monograph for patient populations and drug combinations tested)

Consult the RYBELSUS[®] Product Monograph at RYBELSUSPM-E.ca for more information relating to contraindications, warnings and precautions, conditions of clinical use, adverse reactions, drug interactions, and dosing information, which have not been discussed in this advertisement.

The Product Monograph is also available by calling us at 1-800-465-4334.



I consent to my participation in the Rybelsus[®] Reimbursement Navigation Program. I acknowledge that the services are being delivered by a third party retained by Novo Nordisk. I consent to the collection, use and disclosure of my “personal information” and “personal health information” (as these terms are defined in the Personal Information Protection and Electronic Documents Act) by the third party provider who is delivering services under the Program for the following purposes:

- to communicate with me by phone, email or mail to provide me with requested services under the Program
- to communicate with my healthcare professionals
- to administer the Program, including communication with public and/or private insurers
- to report any adverse events, in compliance with Novo Nordisk’s reporting obligations
- to address any technical complaints in reference to Rybelsus[®]

I acknowledge that the third party’s use and disclosure of my information may involve the storage or processing of my personal information/personal health information outside of Canada and may therefore be subject to different privacy laws than those applicable in Canada, including laws that require the disclosure of personal information/ personal health information to governmental authorities under circumstances that are different than those that apply in Canada.

I further consent to the use of de-identified, aggregated data by Novo Nordisk for the purpose of evaluating the Program and the services provided. I acknowledge that my personal information and personal health information will not be disclosed to Novo Nordisk unless required by law (for instance, in the case of adverse event reporting).

I acknowledge that I may withdraw my consent to participate in the Rybelsus[®] Reimbursement Navigation Program at any time by contacting Novo Nordisk’s third party provider at 1-888-598-0420.

I hereby release Novo Nordisk Canada Inc. and its respective affiliated and subsidiary companies, divisions, directors, officers, employees, agents and contractors from any liability and responsibility for any and all manner of actions, causes of actions, individual and class action claims or demands of any kind whatsoever, whether known, suspected or unknown in law or in equity, including, but not limited to, all claims or potential claims arising out of my voluntary participation in or any injury, loss or death sustained from or arising as a result of my participation in the Rybelsus[®] Reimbursement Navigation Program.